Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics
Aberdeen, UK – 26th February 2021 – NovaBiotics Ltd, the clinical-stage anti-infectives biotechnology company, today announced that it has entered into a licensing agreement with an undisclosed partner to commercialise its NP213 peptide in a topical (brush/paint-on)...
NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.
We are in the midst of a worsening global antimicrobials resistance (AMR) crisis. There is an urgent need for new classes of antibacterial, antifungal and other antimicrobial treatments to address range of challenging infectious diseases that can no longer be resolved with existing drugs. NovaBiotics is a leading innovator in the anti-infectives space and we are designing and developing new medicines that are potential solutions not only to the AMR crisis, but also for complex diseases with an infectious component such as the respiratory infections associated with cystic fibrosis (CF).
NovaBiotics was founded by our CEO, Dr. Deborah O’Neil in 2004 and operates from sites in Aberdeen, UK (R&D headquarters), Dublin, Ireland and Boston (MA), U.S. The Company has a successful track record of invention to clinic of its portfolio of therapeutic candidates. These first in class antimicrobials have been developed from our two proprietary Technology platforms which are underpinned by an extensive, wholly owned intellectual property estate.
The Company’s advanced portfolio of antimicrobial therapeutic candidates targets large and important markets with significant unmet clinical needs, including NM002 (Nylexa®), an antibiotic potentiator for drug resistant bacterial infections including the secondary bacterial infections associated with COVID-19, NM001 (Lynovex®), an orphan drug candidate for cystic fibrosis (CF) and NP339, a novel antifungal peptide in development primarily for the treatment of invasive fungal diseases caused by mould & emerging, drug resistant yeasts. NP423 (Novarifyn®) is a bactericidal peptide for difficult to treat Gram negative and Gram positive bacteria and NP213 (Novexatin®), a potential step change therapy for onychomycosis.